These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22669574)

  • 1. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
    Michaelson JS; Kelly R; Yang L; Zhang X; Wortham K; Joseph IB
    Cancer Biol Ther; 2012 Jul; 13(9):812-21. PubMed ID: 22669574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an Fn14 agonistic antibody as an anti-tumor agent.
    Michaelson JS; Amatucci A; Kelly R; Su L; Garber E; Day ES; Berquist L; Cho S; Li Y; Parr M; Wille L; Schneider P; Wortham K; Burkly LC; Hsu YM; Joseph IB
    MAbs; 2011; 3(4):362-75. PubMed ID: 21697654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.
    Zhou H; Hittelman WN; Yagita H; Cheung LH; Martin SS; Winkles JA; Rosenblum MG
    Cancer Res; 2013 Jul; 73(14):4439-50. PubMed ID: 23722548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
    Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.
    Zhou H; Mohamedali KA; Gonzalez-Angulo AM; Cao Y; Migliorini M; Cheung LH; LoBello J; Lei X; Qi Y; Hittelman WN; Winkles JA; Tran NL; Rosenblum MG
    Mol Cancer Ther; 2014 Nov; 13(11):2688-705. PubMed ID: 25239934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
    Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
    Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
    Lu Z; Wientjes TS; Au JL
    Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TWEAK signals through JAK-STAT to induce tumor cell apoptosis.
    Chapman MS; Wu L; Amatucci A; Ho SN; Michaelson JS
    Cytokine; 2013 Jan; 61(1):210-7. PubMed ID: 23107828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
    Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
    Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.
    Zhou H; Marks JW; Hittelman WN; Yagita H; Cheung LH; Rosenblum MG; Winkles JA
    Mol Cancer Ther; 2011 Jul; 10(7):1276-88. PubMed ID: 21586630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
    Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
    Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.
    Boccia A; Virata C; Lindner D; English N; Pathan N; Brickelmaier M; Hu X; Gardner JL; Peng L; Wang X; Zhang X; Yang L; Perron K; Yco G; Kelly R; Gamez J; Scripps T; Bennett D; Joseph IB; Baker DP
    J Interferon Cytokine Res; 2017 Jan; 37(1):20-31. PubMed ID: 27835061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
    Wahl AF; Donaldson KL; Mixan BJ; Trail PA; Siegall CB
    Int J Cancer; 2001 Aug; 93(4):590-600. PubMed ID: 11477565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
    Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo.
    Trebing J; Lang I; Chopra M; Salzmann S; Moshir M; Silence K; Riedel SS; Siegmund D; Beilhack A; Otto C; Wajant H
    MAbs; 2014; 6(1):297-308. PubMed ID: 24135629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peloruside A Inhibits Growth of Human Lung and Breast Tumor Xenografts in an Athymic nu/nu Mouse Model.
    Meyer CJ; Krauth M; Wick MJ; Shay JW; Gellert G; De Brabander JK; Northcote PT; Miller JH
    Mol Cancer Ther; 2015 Aug; 14(8):1816-23. PubMed ID: 26056149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
    Zhou H; Ekmekcioglu S; Marks JW; Mohamedali KA; Asrani K; Phillips KK; Brown SA; Cheng E; Weiss MB; Hittelman WN; Tran NL; Yagita H; Winkles JA; Rosenblum MG
    J Invest Dermatol; 2013 Apr; 133(4):1052-62. PubMed ID: 23190886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth.
    Kim HM; Kim SA; Park SB; Cho JH; Song SY
    Scand J Gastroenterol; 2017 May; 52(5):577-584. PubMed ID: 28110575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.